Man Jianghong, Shoemake Jocelyn, Zhou Wenchao, Fang Xiaoguang, Wu Qiulian, Rizzo Anthony, Prayson Richard, Bao Shideng, Rich Jeremy N, Yu Jennifer S
Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Department of Anatomic Pathology, Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Cell Rep. 2014 Dec 11;9(5):1812-1826. doi: 10.1016/j.celrep.2014.10.055. Epub 2014 Nov 20.
Different cancer cell compartments often communicate through soluble factors to facilitate tumor growth. Glioma stem cells (GSCs) are a subset of tumor cells that resist standard therapy to contribute to disease progression. How GSCs employ a distinct secretory program to communicate with and nurture each other over the nonstem tumor cell (NSTC) population is not well defined. Here, we show that GSCs preferentially secrete Sema3C and coordinately express PlexinA2/D1 receptors to activate Rac1/nuclear factor (NF)-κB signaling in an autocrine/paracrine loop to promote their own survival. Importantly, Sema3C is not expressed in neural progenitor cells (NPCs) or NSTCs. Disruption of Sema3C induced apoptosis of GSCs, but not NPCs or NSTCs, and suppressed tumor growth in orthotopic models of glioblastoma. Introduction of activated Rac1 rescued the Sema3C knockdown phenotype in vivo. Our study supports the targeting of Sema3C to break this GSC-specific autocrine/paracrine loop in order to improve glioblastoma treatment, potentially with a high therapeutic index.
不同的癌细胞区室通常通过可溶性因子进行通讯以促进肿瘤生长。胶质瘤干细胞(GSCs)是肿瘤细胞的一个亚群,它们抵抗标准治疗从而导致疾病进展。GSCs如何利用独特的分泌程序在非干细胞肿瘤细胞(NSTC)群体中相互通讯并相互滋养,目前尚不清楚。在这里,我们表明GSCs优先分泌Sema3C,并协同表达丛状蛋白A2/D1受体,以在自分泌/旁分泌环路中激活Rac1/核因子(NF)-κB信号传导,从而促进其自身存活。重要的是,Sema3C在神经祖细胞(NPCs)或NSTCs中不表达。破坏Sema3C可诱导GSCs凋亡,但不诱导NPCs或NSTCs凋亡,并抑制胶质母细胞瘤原位模型中的肿瘤生长。引入活化的Rac1可在体内挽救Sema3C敲低表型。我们的研究支持靶向Sema3C以打破这种GSC特异性自分泌/旁分泌环路,从而改善胶质母细胞瘤的治疗,可能具有较高的治疗指数。